Tag Archives: Celgene

Analysts Are Bullish on These Healthcare Stocks: Celgene (CELG), Global Blood Therapeutics (GBT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celgene (CELG – Research Report), Global Blood Therapeutics (GBT – Research Report) and RedHill Biopharma (RDHL – Research Report) with bullish sentiments.

Cowen & Co. Thinks Celgene’s Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Celgene (NASDAQ: CELG) today and set a price target of $150. The company’s shares opened today at $75.55, close to its 52-week low of $72.30. According to TipRanks.com, Nadeau

J.P. Morgan Thinks Celgene’s Stock is Going to Recover

In a report issued on October 8, Cory Kasimov from J.P. Morgan maintained a Buy rating on Celgene (NASDAQ: CELG). The company’s shares closed yesterday at $84.23, close to its 52-week low of $74.13. According to TipRanks.com, Kasimov is a

A Director at Celgene (NASDAQ: CELG) is Selling Shares

Today, a Director at Celgene (NASDAQ: CELG), Ernest Mario, sold shares of CELG for $1.11M. In addition to Ernest Mario, one other CELG executive reported Sell trades in the last month. See today’s analyst top recommended stocks >> Based on

Mizuho Securities Maintains Their Buy Rating on Celgene

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Celgene (NASDAQ: CELG), with a price target of $129. The company’s shares opened today at $88.97. Syed wrote: “We updated our model post the 2Q18

SunTrust Robinson Reiterates a Hold Rating on Celgene

In a report released today, Yatin Suneja from SunTrust Robinson reiterated a Hold rating on Celgene (NASDAQ: CELG), with a price target of $101. The company’s shares opened today at $88.60. According to TipRanks.com, Suneja is a 3-star analyst with